ESPR240719C2500
- 0.11
- +0.01+10.00%
Esperion Therapeutics Newsroom
Notable Analyst Calls This Week: Nike, Micron and FedEx Among Top Picks
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $8
Needham analyst Serge Belanger maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.8% an
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Joseph Pantginis maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate
Express News | HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Shares Rise on Monetization of European Royalties
By Don Nico Forbes Shares in Esperion Therapeutics rose 31% in premarket trading after the company signed a purchase agreement with Omers Life Sciences concerning its Daiichi Sankyo royalties in Euro
Esperion Therapeutics Shares Are Trading Higher After the Company Announced That It Entered Into a Royalty Purchase Agreement With OMERS Life Sciences.
Esperion Therapeutics Shares Are Trading Higher After the Company Announced That It Entered Into a Royalty Purchase Agreement With OMERS Life Sciences.
Express News | Esperion Says It Enters Into A Royalty Purchase Deal With Omers Life Sciences, Under Which It Got $304.7M In Exchange For 100% Interest In Esperion's Royalty Entitlement On Daiichi Sankyo Europe's Net Sales Of Bempedoic Acid Products In Europe
Express News | Esperion Therapeutics Inc - Omers to Receive 15-25% of Net Bempedoic Acid Sales in Europe
Express News | Esperion Therapeutics Inc: Esperion Retains Rights to Receive All Potential Future Milestones of up to $300 Mln
Express News | Esperion Therapeutics Inc: Omers Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Mln
Express News | Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
Esperion Therapeutics(ESPR.US) Officer Sells US$9,418.1 in Common Stock
$Esperion Therapeutics(ESPR.US)$ Officer Foody Joanne M. sold 3,285 shares of common stock on Jun 18, 2024 at an average price of $2.867 for a total value of $9,418.1.Source: Announcement What is stat
Esperion Therapeutics(ESPR.US) Officer Sells US$7,254.24 in Common Stock
$Esperion Therapeutics(ESPR.US)$ Officer Warren Eric sold 2,540 shares of common stock on Jun 18, 2024 at an average price of $2.856 for a total value of $7,254.24.Source: Announcement What is stateme
Esperion Closes Down 16% Following BofA Downgrade
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results.Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, be
Express News | Esperion Therapeutics Shares Are Trading Lower After B of A Securities Downgraded the Stock From Neutral to Underperform
BofA Securities Downgrades Esperion Therapeutics(ESPR.US) to Sell Rating, Cuts Target Price to $2.5
BofA Securities analyst Jason Zemansky downgrades $Esperion Therapeutics(ESPR.US)$ to a sell rating, and adjusts the target price from $2.9 to $2.5.According to TipRanks data, the analyst has a succes
Express News | Esperion Therapeutics Inc : BofA Global Research Cuts Price Objective to $2.5 From $2.9
Express News | Esperion Therapeutics Inc : BofA Global Research Cuts to Underperform From Neutral
Esperion Therapeutics Cut to Underperform From Neutral by B of A Securities
Esperion Therapeutics Cut to Underperform From Neutral by B of A Securities